Document is current

Article History

Received: 25 October 2024

Accepted: 13 February 2025

First Online: 11 April 2025

Declarations

:

: Claire Carette reported receiving personal fees from Boehringer Ingelheim, Axis Santé, Pfizer, Bioprojet Pharma, Novo Nordisk, AstraZeneca, Novartis, Ipsen, MSD, Eli Lilly and Publicis Health and nonfinancial support from Rhythm, Novo Nordisk, MSD, Novartis, Eli Lilly, Sanofi, AstraZeneca, Bristol-Myers Squibb, Abbott, Amgen, Vifor and Fresenius Kabi outside the submitted work. Sébastien Czernichow has received consulting and lecturing fees from Lilly, Fresenius, Novartis, Novo Nordisk, BMS, Boehringer Ingelheim, Pfizer, and Bariatek outside the current manuscript. Claire Rives-Lange: Personal fees from Nestlé Health Science. Supports for attending meetings: Nestlé home care and Fitform. Nicholas Shoung, Aurélie Phan, Elodie Torreton, Anne Dutour, Bruno Detournay have nothing to disclose.

: This study was registered on the Health Data Hub website (T47730692021061). In accordance with current regulations, the study protocol was submitted to the ‘committee for research, studies, and evaluations in the field of health’ (Comité d’Expertise pour les Recherches, les Etudes et les Evaluations dans le domaine de la Santé [CEREES]) for approval and was authorized by the French data protection authority (Commission Nationale de l’Informatique et des Libertés [CNIL], [CNIL authorization number DR-2021-235]). The authorization permitted the implementation of data processing for a study on the epidemiological and economic aspects of BS in France, requiring access to SNIIRAM (système national d’information interrégimes de l’Assurance Maladie) and PMSI (programme de médicalisation des systèmes d’information) data, components of the SNDS for the years 2013 to 2020 (Authorization request no. 921320).